Floatz logo

Risperdal

Conduct Disorder

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 4 / ApprovedDormant
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Conduct Disorder cohort.

Asset / SponsorPhaseRating
Opc-34712
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 1CC
Risperdal
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 4NR

Same molecule, other indications

Risperdal is also rated in:

major depressive disorderDormant
BBB
Indicative ·
78 / 100
View asset →
psychotic disorderDormant
BBB
Indicative ·
77 / 100
View asset →
schizoaffective disorderDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →